dinoprost has been researched along with Lewy-Body-Disease* in 1 studies
1 other study(ies) available for dinoprost and Lewy-Body-Disease
| Article | Year |
|---|---|
Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.
To test the hypothesis that quantification of cerebrospinal fluid (CSF) F(2)-isoprostanes (F(2)-IsoPs), in vivo biomarkers of free radical damage, along with CSF Abeta(42) and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD).. Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10).. Cerebrospinal fluid concentrations of Abeta(42) and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F(2)-IsoP levels were quantified by gas chromatography/mass spectrometry.. Individuals were classified as AD or non-AD by a published method using CSF Abeta(42) and tau levels (95% sensitivity, 50% specificity), by CSF F(2)-IsoP levels greater than 25 pg/mL and Abeta(42) concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F(2)-IsoP, Abeta(42), and tau levels (84% sensitivity, 89% specificity).. Cerebrospinal fluid F(2)-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD. Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Dinoprost; F2-Isoprostanes; Female; Humans; Lewy Body Disease; Male; Peptide Fragments; Reproducibility of Results; Sensitivity and Specificity; tau Proteins | 2001 |